% | $
Quotes you view appear here for quick access.

OncoGenex Pharmaceuticals, Inc. Message Board

  • jetmanbash jetmanbash Nov 30, 2010 9:14 AM Flag

    Competition update:

    Dendreon and Medivation initiated at Wedbush (36.41)
    Wedbush says prostate cancer is the most commonly diagnosed cancer in men. Depending on the state of the disease being local or metastatic, hormone sensitive or castration resistant, asymptomatic or symptomatic, a variety of agents are in use or being developed for the various stages of the disease. Firm says Dendreon (DNDN) and Medivation (MDVN) bring important advancement and options to the treatment of prostate cancer. Dendreon's Provenge is the first immunotherapy ever approved, and the company's goal is to establish it as the standard front line therapy for metastatic castration-resistant prostate cancer. They believe Medivation's MDV3100, together with JNJ's abiraterone, both in Phase III development, are among the most promising agents possessing broad utilities not only in the mCRPC setting, but also the possibility of moving earlier in the disease continuum to the hormone sensitive stage. Firm initiates Dendreon (DNDN) with a Neutral and a $39 tgt and assumes coverage of Medivation (MDVN) with an Outperform and $25 tgt.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.86-0.01(-1.15%)Jul 27 4:00 PMEDT